bevacizumab sold brand name avastin among others medication used treat number types cancers specific eye cancer given slow injection vein intravenous used colon cancer lung cancer glioblastoma renalcell carcinoma many diseases used firstline agerelated macular degeneration given injection eye common side effects used cancer include nose bleeds headache high blood pressure severe side effects include gastrointestinal perforation bleeding allergic reactions blood clots increased risk used eye disease side effects include vision loss retinal bevacizumab monoclonal antibody functions angiogenesis works slowing growth new blood vessels inhibiting vascular endothelial growth factor vegfa words bevacizumab approved medical use united states world health organizations list essential listed use treating eye bevacizumab approved united states february use metastatic colorectal cancer used standard chemotherapy treatment firstline june approved therapy secondline metastatic colorectal approved european medicines agency ema january use colorectal bevacizumab also examined add chemotherapy drugs people nonmetastatic colon cancer data two large randomized studies showed benefit preventing cancer returning potential cause harm eu bevacizumab combination fluoropyrimidinebased chemotherapy indicated treatment adults metastatic carcinoma colon us food drug administration fda approved bevacizumab use firstline advanced nonsquamous nonsmall cell lung cancer combination carboplatinpaclitaxel chemotherapy approval based pivotal study conducted eastern cooperative oncology group demonstrated twomonth improvement overall survival patients treated bevacizumab sandler et al nejm needed preplanned analysis histology demonstrated fourmonth median survival benefit bevacizumab people adenocarcinoma sandler et al jto needed adenocarcinoma represents approximately nonsquamous cell carcinomas lung subsequent european clinical trial avail first reported confirmed significant improvement progressionfree survival shown reck et al ann oncol needed overall survival benefit demonstrated patients treated bevacizumab however may due limited use bevacizumab maintenance treatment avail versus differential effect also apparent european vs us trials bevacizumab colorectal cancer tyagi grothey clin colorectal cancer needed antiangiogenic agent mechanistic rationale stopping bevacizumab disease progression stated another way survival benefits achieved bevacizumab expected used accordance clinical evidence continued disease progression treatmentlimiting side effects another large europeanbased clinical trial bevacizumab lung cancer avaperl reported october barlesi et al eccm needed firstline patients treated bevacizumab plus cisplatinpemetrexed four cycles randomized receive maintenance treatment either bevacizumabpemetrexed bevacizumab alone disease progression maintenance treatment bevacizumabpemetrexed demonstrated reduction risk progression vs bevacizumab alone median pfs vs months maintenance treatment bevacizumabpemetrexed confer significant increase overall survival vs bevacizumab alone follow national comprehensive cancer network recommends bevacizumab standard firstline treatment combination platinumbased chemotherapy followed maintenance bevacizumab disease progressionmedical citation needed higher doses usually given carboplatinbased chemotherapy whereas lower dose usually given cisplatinbased chemotherapymedical citation needed eu bevacizumab addition platinumbased chemotherapy indicated firstline treatment adults unresectable advanced metastatic recurrent nonsmall cell lung cancer predominantly squamous cell bevacizumab combination erlotinib indicated firstline treatment adults unresectable advanced metastatic recurrent nonsquamous nonsmall cell lung cancer epidermal growth factor receptor egfr activating december us food drug administration fda notified intention remove breast cancer indication bevacizumab saying shown safe effective breast cancer combined data four different clinical trials showed bevacizumab neither prolonged overall survival slowed disease progression sufficiently outweigh risk presents patients prevented genentech marketing bevacizumab breast cancer doctors free prescribe bevacizumab label although insurance companies less likely approve offlabel june fda panel unanimously rejected appeal roche panel cancer experts ruled second time avastin longer used breast cancer patients clearing way us government remove endorsement drug june meeting fdas oncologic drug advisory committee last step appeal drugs maker committee concluded breast cancer clinical studies patients taking avastin shown advantage survival rates improvement quality life significant side october fda announced agency revoking agencys approval breast cancer indication bevacizumab concluding drug shown safe effective usecitation needed eu bevacizumab combination paclitaxel indicated firstline treatment adults metastatic breast bevacizumab combination capecitabine indicated firstline treatment adults metastatic breast cancer treatment chemotherapy options including taxanes anthracyclines considered certain renal kidney cancers bevacizumab improves progression free survival time survival time fda approved bevacizumab use metastatic renal cell cancer form kidney following earlier reports eu approval granted eu bevacizumab combination interferon indicated firstline treatment adults advanced andor metastatic renal cell bevacizumab slows tumor growth affect overall survival people fda granted accelerated approval treatment recurrent glioblastoma multiforme may cochrane review deemed good evidence use recurrences many diseases eye agerelated macular degeneration amd diabetic retinopathy damage retina cause blindness blood vessels around retina grow abnormally leak fluid causing layers retina separate abnormal growth caused vegf bevacizumab successfully used inhibit vegf slow bevacizumab used ophthalmologists offlabel use intravitreal agent treatment proliferative neovascular eye diseases particularly choroidal neovascular membrane cnv amd injection mg bevacizumab vitreous cavity performed without significant intraocular many retina specialists noted impressive results setting cnv proliferative diabetic retinopathy neovascular glaucoma diabetic macular edema retinopathy macular edema secondary retinal vein several reviews concluded similar results concerning effects safety obtained using either bevacizumab latter antibody fragment specifically designed approved treatment eye disease us food drug administration fda approved bevacizumab combination chemotherapy stage iii iv ovarian cancer initial surgical operation followed singleagent bevacizumab approval based study addition bevacizumab carboplatin progressionfree survival increased months eu bevacizumab combination carboplatin paclitaxel indicated frontline treatment adults advanced international federation gynecology obstetrics figo stages iiib iiic iv epithelial ovarian fallopian tube primary peritoneal bevacizumab combination carboplatin gemcitabine combination carboplatin paclitaxel indicated treatment adults first recurrence platinumsensitive epithelial ovarian fallopian tube primary peritoneal cancer received prior therapy bevacizumab vegf inhibitors vegf receptortargeted may fda expanded indication olaparib include combination bevacizumab firstline maintenance treatment adults advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbased chemotherapy whose cancer associated homologous recombination deficiency positive status defined either deleterious suspected deleterious brca mutation andor genomic eu bevacizumab combination paclitaxel cisplatin alternatively paclitaxel topotecan people receive platinum therapy indicated treatment adults persistent recurrent metastatic carcinoma bevacizumab usually given intravenously every days colon cancer given combination chemotherapy drug leucovorin oxaliplatin irinotecanmedical citation needed treatment eye diseases injected intravitreously dr philip rosenfeld developed offlabel use bevacizumab agerelated macular bevacizumab used offlabel treat neovascular bevacizumab inhibits growth blood vessels part bodys normal healing maintenance body grows new blood vessels wound healing collateral circulation around blocked atherosclerotic blood vessels one concern bevacizumab interfere normal processes worsen conditions like coronary artery disease peripheral artery main side effects hypertension heightened risk bleeding bowel perforation fatigue infection also advanced lung cancer less half patients qualify nasal septum perforation renal thrombotic microangiopathy december fda warned risk developing perforations body including nose stomach intestines hoffmannla roche announced drug associated cases necrotizing fasciitis patients cases involved patients colorectal cancer patients gastrointestinal perforations fistulas effects largely avoided ophthalmological use since drug introduced directly eye thus minimizing effects rest bodycitation needed neurological adverse events include reversible posterior encephalopathy syndrome ischemic hemorrhagic strokes also protein urine occurs approximately people require permanent discontinuation drug nonetheless presence nephrotic syndrome necessitates permanent discontinuation bevacizumab recombinant humanized monoclonal antibody blocks angiogenesis inhibiting vascular endothelial growth factor vegfa growth factor protein stimulates angiogenesis variety diseases especially cancer binding vegfa bevacizumab act outside cell cases cervical breast cancer taken cells constitutive bevacizumab first available angiogenesis inhibitor united bevacizumab originally derived mouse monoclonal antibody generated mice immunized form recombinant human vascular endothelial growth factor humanized retaining binding region replacing rest human full light chain human truncated heavy chain substitutions resulting plasmid transfected chinese hamster ovary cells grown industrial fermentation bevacizumab recombinant humanized monoclonal antibody became first clinically used angiogenesis development based discovery human vascular endothelial growth factor vegf protein stimulated blood vessel growth laboratory genentech scientist napoleone ferrara later demonstrated antibodies vegf inhibit tumor growth work validated hypothesis judah folkman proposed stopping angiogenesis might useful controlling cancer received first approval united states combination use standard chemotherapy metastatic colon since approved use certain lung cancers renal cancers ovarian cancers glioblastoma multiforme brainmedical citation needed bevacizumab approved breast cancer fda approval revoked november although evidence slowed progression metastatic breast cancer evidence extended life improved quality life caused adverse effects including severe high blood pressure hemorrhagingmedical citation needed fda gave bevacizumab provisional approval metastatic breast cancer subject studies fdas advisory panel recommended july new studies failed show significant benefit fdas advisory panel recommended indication advanced breast cancer genentech requested hearing granted june fda ruled withdraw breast cancer indication november fda approval required genentech market drug indication doctors may sometimes prescribe indication although insurance companies less likely pay drug remains approved breast cancer use countries including funded english nhs cancer drugs fund january proposed remove approved remains cancer drugs fund march fierce debate uk european countries concerning choice prescribing bevacizumab ranibizumab lucentis wet uk part tension one hand european medicines agency medicines healthcare products regulatory agency approved lucentis avastin wet amd interest ensuring doctors use medicines offlabel approved medications indication hand nice uk sets treatment guidelines unable far appraise avastin firstline treatment order save money national health novartis roche respectively marketing rights ownership rights avastin conducted clinical trials get approval avastin wet amd intention companies lobbied treatment guidelines would make avastin firstline treatment governmentfunded studies comparing two drugs published published papers emphasizing risks using avastin wet march european commission approved bevacizumab combination paclitaxel firstline treatment metastatic breast fda approved bevacizumab use breast cancer panel outside advisers voted approval recommendations overruled panel expressed concern data clinical trial show increase quality life prolonging life important benchmarks latestage cancer treatments clinical trial show bevacizumab reduced tumor volumes showed increase progression free survival time based data fda chose overrule recommendation panel advisers decision lauded patient advocacy groups oncologists oncologists felt granting approval latestage cancer therapies prolong increase quality life patients would give license pharmaceutical companies ignore important benchmarks developing new latestage cancer fda announcement national comprehensive cancer network nccn updated nccn clinical practice guidelines oncology nccn guidelines breast cancer affirm recommendation regarding use bevacizumab treatment metastatic breast cancercitation needed us food drug administration removed bevacizumab indication metastatic breast cancer concluding drug shown safe effective specific indication withdrawn use bevacizumab metastatic breast cancer paclitaxel treatment people received chemotherapy metastatic breast cancercitation needed tuesday february roche us biotech unit genentech announced counterfeit avastin distributed united investigation ongoing differences outer packaging make identification bogus drugs simple medical providers roche analyzed three bogus vials avastin found contained salt starch citrate isopropanol propanediol tbutanol benzoic acid difluorinated benzene ring acetone phthalate moiety active ingredients cancer drug according roche levels chemicals consistent whether chemicals harmful concentrations could therefore determined counterfeit avastin traced back egypt entered legitimate supply chains via europe united july two pharming companies plantform pharmapraxis announced plans commercialize biosimilar version bevacizumab made using tobacco expression system collaboration fraunhofer center molecular update september us fda approved amgens biosimilar generic name bevacizumabawwb product name mvasi six cancer january mvasi approved use european february zirabev approved use european zirabev approved medical use united states june australia november june mvasi approved medical use august aybintio approved use european september equidacent approved use european january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product alymsys intended treatment carcinoma colon rectum breast cancer nonsmall cell lung cancer renal cell cancer epithelial ovarian fallopian tube primary peritoneal cancer carcinoma alymsys approved medical use european union march january onbevzi approved medical use european june june zirabev approved medical use oyavas approved medical use european union march abevmy approved medical use european union april australia september september bambevi approved medical use bevacip bevaciptin approved medical use australia november november abevmy aybintio approved medical use april bevacizumabmaly alymsys approved medical use united august vegzelma approved medical use european september bevacizumabadcd vegzelma approved medical use united june enzene biosciences launched bevacizumab biosimilar study released april found bevacizumab effective preventing recurrences nonmetastatic colon cancer following bevacizumab tested ovarian cancer shown improvement progressionfree survival overall glioblastoma multiforme failed improve overall bevacizumab investigated possible treatment pancreatic cancer addition chemotherapy studies shown improvement may also cause higher rates high blood pressure bleeding stomach intestine intestinal perforationsmedical citation needed drug also undergone trials addition established chemotherapy protocols surgery treatment pediatric sarcomas bevacizumab studied treatment cancers grow nerve connecting ear httpsenwikipediaorgwikibevacizumab